Introduction
Atosiban Acetate is a synthetic oxytocin receptor antagonist used primarily in obstetrics to delay preterm labor. By blocking the action of oxytocin, which is a hormone that stimulates uterine contractions, Atosiban helps to manage and delay premature labor in pregnant women.
Uses
Atosiban Acetate is used to inhibit premature labor in pregnant women who are between 24 and 33 weeks of gestation. It is specifically used to manage contractions in cases of preterm labor and reduce the risk of premature birth, which can help in prolonging pregnancy to allow for better fetal development.
| Brand Name | Atosiban Acetate |
|---|---|
| Type | |
| Weight | |
| Generic | Atosiban Acetate |
| Manufacturer | |
| Available in | English বাংলা |
Mechanism of Action
Atosiban works as a competitive antagonist at the oxytocin receptors in the uterus. By blocking the binding of oxytocin to these receptors, Atosiban inhibits uterine contractions and delays the onset of labor. This action helps to reduce the frequency and intensity of contractions during preterm labor.
How Long Does It Take to Work?
Atosiban generally starts to reduce uterine contractions within a few hours of administration. The full effect can be observed within 24 to 48 hours. The duration of action may vary depending on individual patient response and dosage.
Absorption
Atosiban is administered intravenously, allowing for direct absorption into the bloodstream. It has a rapid onset of action due to this method of administration, and peak plasma concentrations are achieved quickly following infusion.
Route of Elimination
Atosiban is primarily metabolized in the liver, and its metabolites are excreted via the urine. Only a small portion of the drug is eliminated unchanged. The elimination process is typically efficient, with the drug being cleared from the system within a few hours to days.
Dosage
Atosiban is administered intravenously in three successive stages: an initial bolus dose (6.75 mg), performed with Atosiban 6.75 mg/0.9 ml solution for injection, immediately followed by a continuous high dose infusion (loading infusion 300 micrograms/min) of Atosiban 37.5 mg/5 ml concentrate for solution for infusion during three hours, followed by a lower dose of Atosiban 37.5 mg/5 ml concentrate for solution for infusion (subsequent infusion 100 micrograms/min) up to 45 hours. The duration of the treatment should not exceed 48 hours. The total dose given during a full course of Atosiban therapy should preferably not exceed 330.75 mg of atosiban.The dosage of Atosiban is typically administered as a continuous intravenous infusion. The standard dosing regimen includes an initial bolus of 6.75 mg, followed by a continuous infusion of 18 mg/hour. Dosage adjustments may be necessary based on the clinical response and individual patient factors.
Administration
Atosiban is given intravenously, starting with a bolus dose followed by a continuous infusion. The infusion rate and duration of therapy depend on the clinical situation and response to treatment. It should be administered under the supervision of a healthcare professional.
Side Effects
Common side effects of Atosiban may include nausea, headache, dizziness, and gastrointestinal disturbances. Some women may experience localized reactions at the infusion site, such as pain or swelling. Serious side effects are rare but may include allergic reactions or cardiovascular effects.
Toxicity
Acute toxicity from Atosiban is uncommon but can occur. Symptoms of overdose may include severe hypotension or other cardiovascular symptoms. In the case of suspected overdose, discontinue the drug and provide supportive care as needed. Monitoring and appropriate management are essential.
Precautions
Precautions should be taken in patients with a history of cardiovascular disease or renal impairment. It is important to monitor maternal and fetal well-being during treatment. Regular assessments are required to manage any potential side effects or complications.
Interaction
Atosiban may interact with other medications that affect uterine contractions or those with potential cardiovascular effects. It is important to review all concurrent medications with a healthcare provider to avoid potential interactions and adverse effects.
Disease Interaction
Use of Atosiban should be approached with caution in patients with significant cardiovascular disease, renal impairment, or liver dysfunction. Close monitoring and dose adjustments may be necessary in these cases to ensure safety and efficacy.
Drug Interaction
Atosiban may interact with drugs that affect the cardiovascular system or those used for managing preterm labor. This includes other tocolytics or medications affecting blood pressure. Drug interactions should be carefully reviewed to avoid potential adverse effects.
Food Interactions
There are no significant food interactions with Atosiban, as it is administered intravenously and bypasses the gastrointestinal system. Dietary considerations are not typically required for this medication.
Pregnancy Use
Atosiban is used specifically during pregnancy to manage preterm labor. It is intended for use in pregnant women between 24 and 33 weeks of gestation. Its use should be closely monitored by a healthcare provider to ensure safety for both the mother and fetus.
Lactation Use
The effects of Atosiban on lactation are not well-studied, but it is generally not used during breastfeeding as it is primarily used to manage labor and is not expected to be used long-term. Consult a healthcare provider for guidance if lactation is a concern.
Acute Overdose
Acute overdose of Atosiban can lead to severe hypotension and cardiovascular issues. Immediate discontinuation of the infusion and supportive care are necessary. Monitoring of vital signs and supportive treatment will be required to manage any overdose-related symptoms.
Contraindication
Atosiban is contraindicated in patients with hypersensitivity to the drug or its components. It should also be avoided in cases where the continuation of pregnancy is not indicated, such as in severe preeclampsia or other conditions where preterm labor cannot be managed.
Use Direction
Follow the prescribed dosage and administration instructions carefully. Atosiban should be administered under the supervision of a healthcare professional with monitoring of maternal and fetal well-being throughout the treatment period.
Storage Conditions
Atosiban should be stored at controlled room temperature, away from light and moisture. It should be kept out of reach of children and used according to the manufacturer's guidelines. Proper storage ensures the medication's efficacy and safety.
Volume of Distribution
The volume of distribution for Atosiban is approximately 0.2 to 0.4 liters per kilogram. This reflects its distribution within the extracellular space and its ability to reach target tissues.
Half Life
The half-life of Atosiban is approximately 1.5 to 2 hours, reflecting its relatively short duration of action. This necessitates continuous infusion for effective management of preterm labor.
Clearance
Atosiban is primarily cleared through the liver and kidneys. The clearance rate can be influenced by liver and renal function, and monitoring may be necessary in patients with hepatic or renal impairment.
See in details version Atosiban Acetate also Atosiban Acetate in bangla
